Recro Pharma Inc (NASDAQ:REPH)’s share price traded up 5.1% on Thursday . The company traded as high as $9.87 and last traded at $9.60. 571,481 shares traded hands during mid-day trading, an increase of 222% from the average session volume of 177,578 shares. The stock had previously closed at $9.13.
A number of equities analysts have weighed in on the stock. Oppenheimer set a $18.00 price objective on shares of Recro Pharma and gave the company a “buy” rating in a research report on Wednesday, February 20th. Zacks Investment Research cut shares of Recro Pharma from a “strong-buy” rating to a “hold” rating in a research report on Saturday, February 23rd. Janney Montgomery Scott reissued a “buy” rating and issued a $13.00 price objective on shares of Recro Pharma in a research report on Thursday, January 31st. Finally, ValuEngine raised shares of Recro Pharma from a “hold” rating to a “buy” rating in a research report on Tuesday, November 27th. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $11.85.
The company has a debt-to-equity ratio of 4.04, a quick ratio of 2.08 and a current ratio of 2.45. The stock has a market cap of $201.85 million, a price-to-earnings ratio of -3.86 and a beta of -0.30.
Recro Pharma (NASDAQ:REPH) last issued its earnings results on Tuesday, February 19th. The specialty pharmaceutical company reported ($0.58) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.17. The business had revenue of $17.78 million for the quarter, compared to analyst estimates of $16.01 million. Recro Pharma had a negative net margin of 103.07% and a negative return on equity of 472.58%. On average, analysts anticipate that Recro Pharma Inc will post -2.96 EPS for the current year.
Institutional investors have recently modified their holdings of the company. Northern Trust Corp raised its stake in Recro Pharma by 28.0% during the second quarter. Northern Trust Corp now owns 220,965 shares of the specialty pharmaceutical company’s stock worth $1,109,000 after acquiring an additional 48,297 shares during the period. Panagora Asset Management Inc. raised its stake in Recro Pharma by 1,361.1% during the third quarter. Panagora Asset Management Inc. now owns 189,128 shares of the specialty pharmaceutical company’s stock worth $1,345,000 after acquiring an additional 176,184 shares during the period. Virtu Financial LLC acquired a new stake in Recro Pharma during the third quarter worth about $156,000. Renaissance Technologies LLC raised its stake in Recro Pharma by 26.0% during the third quarter. Renaissance Technologies LLC now owns 480,500 shares of the specialty pharmaceutical company’s stock worth $3,416,000 after acquiring an additional 99,200 shares during the period. Finally, Engine Capital Management LP raised its stake in Recro Pharma by 21.0% during the third quarter. Engine Capital Management LP now owns 473,484 shares of the specialty pharmaceutical company’s stock worth $3,366,000 after acquiring an additional 82,177 shares during the period. Institutional investors and hedge funds own 55.47% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This report was first reported by Zolmax and is the property of of Zolmax. If you are accessing this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright legislation. The original version of this report can be accessed at https://zolmax.com/investing/recro-pharma-reph-trading-5-1-higher/2980686.html.
About Recro Pharma (NASDAQ:REPH)
Recro Pharma, Inc, a specialty pharmaceutical company, develops and commercializes products for hospital and related acute care settings. The company operates in two segments, Acute Care, and Contract Development and Manufacturing. Its lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain.
Recommended Story: What is the Coverage Ratio?
Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.